DTC Price Comparisons To Get FDA Scrutiny
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA wants to measure consumer understanding of product safety and efficacy when ads compare the prices of two drugs amid concerns they could imply the compared drugs are interchangeable.
You may also be interested in...
Rx Ad Studies Target Risk Info Location, Efficacy Framing, Oncology Products
Flurry of new studies brings tally of FDA research projects on Rx drug promotion to 43; the 14 in progress and 7 pending peer review or recently published have a total cost of $15.5m.
FDA’s Biggest DTC Advertising Study Eyes Online Promotion
The agency has 11 research projects under way, including a $2 million study of online Rx drug promotion; pharma spending on direct-to-consumer advertising declined in 2012 with biggest spends on Cymbalta and Cialis ads.
Makena’s Orphan Exclusivity Is “Nullified” By FDA’s Compounding Policy, KV Suit Says
KV seeks a court order requiring FDA to desist from permitting importation of unapproved API for compounded hydroxyprogesterone and to state its intent to take enforcement action against compounders.